ProCE Banner Activity

A New Era in Post-HCT CMV Management

Clinical Thought
How has the approval of letermovir prophylaxis altered post-HCT CMV management? Here’s my take.

Released: January 16, 2018

Expiration: January 15, 2019

No longer available for credit.

Share

Faculty

Genovefa A. Papanicolaou

Genovefa A. Papanicolaou, MD

Professor
Department of Medicine
Weill Medical College
Cornell University
Attending Physician
Director,
Clinical Trials
Infectious Disease Service
Memorial Sloan Kettering
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck & Co., Inc.

Faculty Disclosure

Primary Author

Genovefa A. Papanicolaou, MD

Professor
Department of Medicine
Weill Medical College
Cornell University
Attending Physician
Director,
Clinical Trials
Infectious Disease Service
Memorial Sloan Kettering
New York, New York

Genovefa A. Papanicolaou, MD, has disclosed that she has received consulting fees from Astellas, Chimerix, and Shire and funds for research support from Astellas, Chimerix, and Merck.